ZyVersa Therapeutics, Inc. Warrants
ZVSAW
ZVSAW was delisted on the 20th of December, 2022.
19 hedge funds and large institutions have $482K invested in ZyVersa Therapeutics, Inc. Warrants in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
19% more funds holding
Funds holding: 16 → 19 (+3)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
74% less capital invested
Capital invested by funds: $1.84M → $482K (-$1.36M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$53.6K |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$26.6K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$15K |
| 4 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$3.23K |
| 5 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$2.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.48M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$16.4K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$10.1K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$168 |
ZVSAW Hedge Fund Activity: Q3 2022 in Review
19 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q3 2022, worth a combined $482K — down 74% from $1.84M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ZVSAW positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Yakira Capital Management, opening a new position worth an estimated $53.6K. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.48M sold.
- 19 institutional investors held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q3 2022, up from 16 in Q2 2022.
- Funds reported $482K of ZyVersa Therapeutics, Inc. Warrants stock for Q3 2022, down 74% quarter-over-quarter.
- 4 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q3 2022 and 1 closed out, a net change of +3 holders.
- The largest ZyVersa Therapeutics, Inc. Warrants buyer in Q3 2022 was Yakira Capital Management, an estimated $53.6K added.
- The largest ZyVersa Therapeutics, Inc. Warrants seller in Q3 2022 was Mangrove Partners, an estimated $1.48M sold.
Based on aggregated 13F filings for Q3 2022.